Led by Lorenzo Leggio, MD, PhD of The National Institute on Drug Abuse (NIDA) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the research outlines how activation of GLP-1 receptors in the brain may modulate reward circuits involved in substance craving and dependence
However, in the initial stages, the patients symptoms are not obvious, which can delay patient evaluation and diagnosis
Trulicity can help lower A1C levels and may also provide some kidney-related benefits
Underscoring the importance that direct cholesterol engagement has in the modulation of GLP-1R function, the changes in cholesterol binding and plasma membrane behaviours introduced by the V229A substitution led to significant effects on GLP-1R trafficking and signalling in beta cells: V229A caused a decrease in GLP-1R recruitment to CCPs and receptor internalisation, accompanied by an increase in G s (measured with mini-G s ) and -arrestin 2 engagement, as well as increased plasma membrane recycling following exendin-4 stimulation
Disclaimer: All products referenced by Licensed Peptides are intended exclusively for laboratory research purposes
For a deeper look at how this treatment class works, see our guide on what GLP-1 therapy is and how it supports weight loss